CYB004 – which is being developed for anxiety disorders – has shown that it has a similar onset of effect and dose profile to IV DMT when inhaled.
Cybin has reported positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated DMT molecule, CYB004, delivered via inhalation.
The results demonstrated that, when inhaled, the compound has significant advantages over both IV DMT and inhaled DMT, including a longer duration of action, and improved bioavailability.
Cybin CEO, Doug Drysdale, commented: “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability.
“CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic.
“As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.
“Cybin’s approach to psychedelic drug development enables the control of many biological factors, including improving the way a drug is metabolised and managing some adverse effects. In its natural form, DMT is unstable and not orally bioavailable.
“Based on these preclinical studies, we believe CYB004 has the potential to overcome these issues. These results also provide strong evidence that an inhaled delivery mode may be able to address the limitations of IV DMT and could be widely applicable to a variety of psychedelics,”
Cybin is planning on submitting a regulatory filing for a pilot study in the second quarter of 2022 and to initiate the pilot study in the third quarter of 2022, and also recently announced that the World Intellectual Property Organization published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules, including inhaled CYB004.
[activecampaign form=52]
